Sotera Health Co.

SHC

Nasdaq; healthcare; SIC 8090, Services-Misc Health & Allied Services, NEC; CIK 0001822479

C/D

on the C/D boundary of 305 graded peers in healthcare

rank 177 of 305; percentile 57.9; sampling error 2.8 points; lower is stronger



C/D, the tortoise



Scoreboard

Profitability	B/C	percentile 40.9
Solvency	D	percentile 65.1
Growth and financing	C	percentile 43.3
Reliability	0.94 AUC	filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets	total assets $3.3B
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	none triggered	not computable: distress
Inputs computable	8 of 13	
Graded from	filings received through Feb 24, 2026	271 days before the rescan; latest periodic filing 10-Q received Nov 3, 2026
Last close	$15.92	2026-11-20; market equity $4.5B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health®. We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. In 2025, our customers included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies (based on revenue).

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 40.9						
Gross profitability	19.8%	32.8%		64.6	346	2025-12-31
Return on invested capital	not computable	9.6%				

latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(6.6%)	(6.7%)	55.5	756	2025-12-31
Gross margin stability, five years	0.4 pts	2.8 pts	2.5	237	2025-12-31
Solvency, sleeve percentile 65.1					
Altman Z double-prime	not computable	0.31			
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31					
Net debt to EBITDA	not computable	1.82x			
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31					
Interest coverage	not computable	(3.61x)			
one or more required annual facts are missing					
Current ratio	2.46x	2.68x	65.1	781	2025-12-31
Growth and financing, sleeve percentile 43.3					
Revenue growth, three-year compound	5.1%	9.6%	60.2	400	2025-12-31
Free cash flow growth, three-year compound	16.0%	11.1%	48.4	94	2025-12-31
Reinvestment rate	not computable	33.9%			
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31					
Asset growth, three years	1.5%	3.2%	48.8	663	2025-12-31
Net share issuance, one year	0.3%	1.6%	16.0	626	2026-02-17

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
172	Nexgel, Inc. (NXGL)	56.2	C	late filer
173	Perrigo Co. plc (PRGO)	56.6	C	
174	Cryo Cell International Inc. (CCEL)	56.9	C	distress
175	Teladoc Health, Inc. (TDOC)	57.2	C	fortress balance sheet
176	Emergent BioSolutions Inc. (EBS)	57.6	C/D	
177	Sotera Health Co. (SHC)	57.9	C/D	
178	Abbott Laboratories (ABT)	58.2	C/D	
179	Medtronic plc (MDT)	58.6	C/D	
180	Neuronetics, Inc. (STIM)	58.9	C/D	
181	Cooper Companies, Inc. (COO)	59.2	C/D	
182	Aquestive Therapeutics, Inc. (AQST)	59.5	C/D	

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	11.4%	(1.7%)	56
Distance from 52-week high	(18.7%)	(33.0%)	67
EBIT to enterprise value	4.7%	0.5%	75
Free cash flow yield	3.3%	0.6%	65
Book value to price	0.16	0.29	32
Sales to price	0.26	0.38	37

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	not computable	13.5%	
Relative strength against the sector, log excess return	(0.06)	(0.19)	56
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 7 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$412.4M
Operating cash flow, four quarters	$331.6M
Months of runway	not finite
Days since last periodic filing	19 (10-Q received Nov 3, 2026)
Median daily dollar volume, 63 sessions	$35.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$645.5M	2025-12-31	2026-02-24	10-K	26-000015
2	assets	us-gaap:Assets	$3.3B	2025-12-31	2026-02-24	10-K	26-000015
3	operating income	us-gaap:OperatingIncomeLoss	$297.6M	2024-12-31	2025-02-27	10-K	25-000015
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$113.9M	2024-12-31	2026-02-24	10-K	26-000015
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$69.5M	2024-12-31	2026-02-24	10-K	26-000015
6	total debt	us-gaap:LongTermDebt	$2.2B	2024-12-31	2026-02-24	10-K	26-000015
7	book equity	us-gaap:StockholdersEquity	$404.9M	2024-12-31	2026-02-24	10-K	26-000015
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$277.2M	2024-12-31	2026-02-24	10-K	26-000015
9	total debt	us-gaap:LongTermDebt	$2.2B	2023-12-31	2025-02-27	10-K	25-000015
10	book equity	us-gaap:StockholdersEquity	$443.7M	2023-12-31	2026-02-24	10-K	26-000015
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$296.4M	2023-12-31	2025-02-27	10-K	25-000015
12	net income	us-gaap:NetIncomeLoss	$77.9M	2025-12-31	2026-02-24	10-K	26-000015
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$287.2M	2025-12-31	2026-02-24	10-K	26-000015
14	assets	us-gaap:Assets	$3.1B	2024-12-31	2026-02-24	10-K	26-000015
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.2B	2025-12-31	2026-02-24	10-K	26-000015
16	gross profit	us-gaap:GrossProfit	$602.3M	2024-12-31	2026-02-24	10-K	26-000015
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2024-12-31	2026-02-24	10-K	26-000015
18	gross profit	us-gaap:GrossProfit	$577.2M	2023-12-31	2026-02-24	10-K	26-000015
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.0B	2023-12-31	2026-02-24	10-K	26-000015
20	gross profit	us-gaap:GrossProfit	$557.0M	2022-12-31	2025-02-27	10-K	25-000015
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.0B	2022-12-31	2025-02-27	10-K	25-000015
22	gross profit	us-gaap:GrossProfit	$518.7M	2021-12-31	2024-02-27	10-K	24-000011
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$931.5M	2021-12-31	2024-02-27	10-K	24-000011
24	current assets	us-gaap:AssetsCurrent	$526.0M	2024-12-31	2026-02-24	10-K	26-000015
25	current liabilities	us-gaap:LiabilitiesCurrent	$191.0M	2024-12-31	2026-02-24	10-K	26-000015
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$610.0M	2024-12-31	2026-02-24	10-K	26-000015
27	liabilities	us-gaap:Liabilities	$2.7B	2024-12-31	2026-02-24	10-K	26-000015

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$84.3M	2024-12-31	2026-02-24	10-K	26-000015
29	current assets	us-gaap:AssetsCurrent	$613.4M	2025-12-31	2026-02-24	10-K	26-000015
30	current liabilities	us-gaap:LiabilitiesCurrent	$249.6M	2025-12-31	2026-02-24	10-K	26-000015
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$138.0M	2025-12-31	2026-02-24	10-K	26-000015
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$224.2M	2024-12-31	2026-02-24	10-K	26-000015
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$179.1M	2024-12-31	2026-02-24	10-K	26-000015
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$147.7M	2023-12-31	2026-02-24	10-K	26-000015
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$215.0M	2023-12-31	2026-02-24	10-K	26-000015
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$278.0M	2022-12-31	2025-02-27	10-K	25-000015
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$182.4M	2022-12-31	2025-02-27	10-K	25-000015
38	current assets	us-gaap:AssetsCurrent	$557.2M	2023-12-31	2025-02-27	10-K	25-000015
39	current liabilities	us-gaap:LiabilitiesCurrent	$230.7M	2023-12-31	2025-02-27	10-K	25-000015
40	assets	us-gaap:Assets	$3.1B	2023-12-31	2025-02-27	10-K	25-000015
41	assets	us-gaap:Assets	$3.1B	2022-12-31	2024-02-27	10-K	24-000011
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	284,392,079	2026-02-17	2026-02-24	10-K	26-000015
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	283,473,342	2025-02-20	2025-02-27	10-K	25-000015

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.